Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $574,678.72 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 23,323 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $24.64, for a total value of $574,678.72. Following the transaction, the director now owns 9,981 shares of the company’s stock, valued at approximately $245,931.84. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Daniel Bradbury also recently made the following trade(s):

• On Monday, April 8th, Daniel Bradbury sold 2,400 shares of Castle Biosciences stock. The stock was sold at an average price of $20.45, for a total value of $49,080.00.
• On Thursday, April 4th, Daniel Bradbury sold 9,152 shares of Castle Biosciences stock. The shares were sold at an average price of $21.45, for a total transaction of $196,310.40.
• On Monday, March 4th, Daniel Bradbury sold 23,323 shares of Castle Biosciences stock. The stock was sold at an average price of $20.68, for a total transaction of $482,319.64.

Castle Biosciences Trading Up 3.7 %

CSTL opened at $24.42 on Friday. The firm has a 50 day simple moving average of $20.81 and a 200 day simple moving average of $20.61. Castle Biosciences, Inc. has a fifty-two week low of $9.26 and a fifty-two week high of $26.70. The company has a market cap of $674.24 million, a price-to-earnings ratio of -21.23 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.25 and a quick ratio of 9.02.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.74. The company had revenue of $66.12 million for the quarter, compared to the consensus estimate of $51.32 million. Castle Biosciences had a negative return on equity of 7.91% and a negative net margin of 12.28%. On average, sell-side analysts anticipate that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in shares of Castle Biosciences by 7.0% in the 4th quarter. Principal Financial Group Inc. now owns 1,585,673 shares of the company’s stock valued at $34,219,000 after buying an additional 103,503 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Castle Biosciences by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,439,388 shares of the company’s stock worth $24,311,000 after acquiring an additional 11,967 shares during the period. Bellevue Group AG boosted its stake in Castle Biosciences by 0.4% in the 4th quarter. Bellevue Group AG now owns 1,232,378 shares of the company’s stock worth $26,595,000 after purchasing an additional 4,347 shares during the period. Deerfield Management Company L.P. Series C bought a new stake in shares of Castle Biosciences in the third quarter valued at about $15,988,000. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of Castle Biosciences by 112.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 547,403 shares of the company’s stock worth $9,246,000 after buying an additional 289,252 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Scotiabank boosted their target price on Castle Biosciences from $33.00 to $37.00 and gave the stock a “sector outperform” rating in a report on Friday, March 1st. KeyCorp increased their price objective on shares of Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, March 1st. Finally, Robert W. Baird upped their target price on shares of Castle Biosciences from $33.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.